The report on Pfizer was published on April 11, 2026. Share the report or generate your own report on Finsight Alpha.
Pfizer
Bearish/NeutralExecutive Summary
Investors are left questioning how Pfizer will sustain profitability amid a backdrop of declining revenues and increasing financial pressures. The company reported a revenue decline to $62.58 billion in FY2025, down from $63.63 billion in FY2024, indicating significant challenges in maintaining its market position. This downturn is compounded by a concerning payout ratio of 125.75 percent, which raises doubts about the sustainability of its dividend payments as cash flow struggles to keep pace with obligations.
Furthermore, Pfizer's financial health is further jeopardized by declining cash flow per share and an extended cash conversion cycle, which suggests potential liquidity issues that could hinder operational efficiency. The current ratio of 1.16 provides only a slight buffer against short-term liabilities, and the increasing days of inventory outstanding signal possible inefficiencies in inventory management. Taken together, these factors create a precarious financial landscape for Pfizer, making it imperative for investors to approach with caution.
Given the combination of revenue decline, high payout ratios, and liquidity concerns, it is clear that Pfizer faces significant challenges ahead. Investors should remain vigilant as these financial strains could impact the company's ability to invest in new therapies and maintain its competitive edge in the pharmaceutical sector. The outlook remains Bearish/Neutral.
Next reported earnings: Tuesday, 5 May 2026, before market open.
Key Metrics
| Market Cap | $153.02 B | |
| 6-Month Share Price Change | 8.60% | |
| Revenue (TTM) | $62.58 B | |
| EBITDA (TTM) | $15.10 B | |
| EPS (TTM) | $1.37 | |
| Operating Cash Flow (TTM) | $11.70 B | |
| Free Cash Flow (TTM) | $9.08 B | |
| Cash and cash equivalents | $1.14 B | |
| P/E Ratio (TTM) | 19.68 | |
| Price/Book (TTM) | 1.77 | |
| Debt/Equity | 0.78 | |
| Current Ratio | 1.16 | |
| Dividend Yield (TTM) | 6.39% |
Tap or click the i icon for a metric definition.
The Pfizer Story
Founded in 1849 and headquartered in New York City, Pfizer has evolved from a small chemical company into one of the largest pharmaceutical firms in the world. Initially focused on producing fine chemicals, Pfizer made a significant pivot in the 20th century by investing heavily in research and development, leading to breakthroughs in antibiotics, vaccines, and other critical medications.
One of the company's major milestones came in the 1990s with the launch of Viagra, which not only transformed the treatment of erectile dysfunction but also established Pfizer as a leader in the pharmaceutical industry. The company's commitment to innovation continued with the development of the COVID-19 vaccine in partnership with BioNTech, a rapid response that showcased its capabilities in biotechnology and vaccine development.
However, the landscape of pharmaceuticals is ever-changing. Pfizer has faced challenges, including patent expirations and increasing competition from generic drugs. In response, the company has shifted its focus toward specialty medicines and rare diseases, aiming to diversify its portfolio and maintain growth. Taken together, these strategies reflect Pfizer's adaptability and ongoing commitment to improving global health.
Macro Industry Position
The Drug Manufacturers - General industry thrives on the interplay of payer and reimbursement pressure, employment costs, and the cost of capital for research and development. These factors significantly influence cash flow and profit margins. Leading firms in this sector include Johnson & Johnson, Merck & Co., and Bristol-Myers Squibb, each recognized for their extensive portfolios and market presence. As competition intensifies, companies must balance innovation with cost management to maintain profitability and market share.
Pfizer's distribution strategy leverages a vast network that includes hospitals, pharmacies, and direct-to-consumer channels. The company offers a diverse range of products, from vaccines to specialty medications, addressing various health conditions. Key competitors such as AstraZeneca and Gilead Sciences also focus on innovation and market access, creating a dynamic environment where product differentiation is crucial. Pfizer's recent advancements in biotechnology further position it as a leader in the sector, enhancing its competitive edge.
The current macroeconomic environment presents challenges for the Drug Manufacturers - General industry. With consumer prices rising, companies face increased pressure on margins and pricing strategies. Long-term government bond yields remain steady, impacting the cost of capital for research initiatives. As demographic demand for healthcare continues to grow, firms like Pfizer must navigate regulatory risks while adapting to changing reimbursement landscapes. This environment underscores the importance of strategic investment in innovation to sustain growth and profitability.
Pfizer's ability to maintain its market position hinges on consumer spending power, which is currently challenged by rising prices. The US inflation rate stands at 3.3 % year over year, impacting household budgets and potentially limiting discretionary spending on healthcare products. In response, the Federal Reserve has set the policy rate at 5.25 %, influencing the cost of capital for research and development. Pfizer must navigate these pressures while ensuring that its innovative pipeline remains funded. Euro-area inflation is slightly lower at 3.4 % year over year, which may affect Pfizer's pricing strategies in that region. Additionally, the US 10-year yield is at 4.29 %, shaping the financial landscape for long-term investments in R&D and acquisitions.
Bottom line: The Drug Manufacturers - General industry faces a complex interplay of payer pressures and rising costs, with Pfizer positioned to adapt through strategic innovation. However, the current macroeconomic environment, characterized by inflationary pressures and elevated interest rates, poses significant challenges. Pfizer's focus on maintaining profitability while investing in new therapies will be crucial as it navigates these economic headwinds.
Recent Developments
On April 6, 2026, Pfizer announced advancements in the application of artificial intelligence in cancer care. The company highlighted how AI technologies are reshaping treatment protocols and improving patient outcomes. This initiative aligns with Pfizer's ongoing commitment to innovation in healthcare, particularly in oncology, where AI can enhance diagnostic accuracy and treatment personalization.[1]
On April 9, 2026, Pfizer's stock performance was compared to other branded pharmaceutical companies in a report that analyzed fourth quarter earnings. The analysis noted that Pfizer faced challenges but also highlighted areas of strength in its product lineup. The report provided insights into how Pfizer's financial results stacked up against competitors, indicating a mixed performance in the sector.[2]
On April 8, 2026, Pfizer decided to vacate its underutilized office space in South San Francisco, transitioning employees to remote roles. This move was part of a broader strategy to optimize operational efficiency and reduce overhead costs. The company aimed to adapt to changing work environments and enhance productivity through remote work arrangements.[3]
For investors, these updates suggest that Pfizer is actively pursuing innovative strategies to enhance its market position and operational efficiency. The focus on AI in cancer care may open new revenue streams, while the decision to reduce physical office space could lead to cost savings. However, the mixed performance in earnings compared to competitors indicates that investors should remain cautious and monitor how these developments impact Pfizer's overall financial health moving forward.[2][3]
Sources
- [1] How AI Is Already Reshaping Cancer Care - Pfizer (Apr 6, 2026)
- [2] Q4 Earnings Highs And Lows: Pfizer (NYSE:PFE) Vs The Rest Of The Branded Pharmaceuticals Stocks - Yahoo Finance (Apr 9, 2026)
- [3] Pfizer walks away from 'underutilized' office space in South San Francisco, transitions employees to remote roles - Fierce Pharma (Apr 8, 2026)
Financial Deep-Dive
Welcome to the Financial Deep-Dive. The eight tabs below organise Pfizer's financial data into valuation, profitability, per-share data, leverage, liquidity, efficiency, working-capital, and R&D. Each tab presents financial metrics and trend charts for its category, along with key strengths and weaknesses. Click on any measure for a clear definition and insight into its relevance for investors. At the bottom, you'll find a detailed Financial Health Summary outlining Pfizer's financial condition based on their most recent accounts.
Financial Health Summary
Pfizer reported FY2025 revenue of $62.58 billion, a decline from $63.63 billion in FY2024. EBITDA for FY2025 was $15.10 billion, down from $18.13 billion the previous year. In the latest quarter, Pfizer generated revenue of $17.56 billion and EBITDA of $0.76 billion, supported by an operating cash flow of $11.71 billion.
The market capitalization stands at $153.02 billion, with a price-to-earnings ratio of 19.68 and a price-to-sales ratio of 2.45. These figures suggest a moderate valuation relative to earnings and sales. While the debt-to-equity ratio is a manageable 0.78, the liquidity picture is mixed; although Pfizer holds $1.14 billion in cash and cash equivalents, the current ratio of 1.16 indicates only a slight buffer against short-term liabilities. The payout ratio of 125.75% raises concerns about sustainability, especially given the declining cash per share.
However, the pressure on operating cash flow per share is evident, having decreased over the reporting period, which could signal challenges in cash generation. Additionally, the cash conversion cycle has lengthened, indicating that Pfizer is tying up more days in working capital, which may hinder operational efficiency. Days of inventory outstanding have also increased, suggesting potential issues with inventory management, while days of payables outstanding have risen, indicating slower payments to suppliers.
Verdict: Pfizer faces significant cash generation challenges, compounded by an extended cash conversion cycle and rising inventory days. These factors could impact its financial flexibility and overall operational efficiency moving forward.
Risks and Concerns
Pfizer's operational landscape is increasingly complex, marked by rising inflation and heightened competition. The US inflation rate currently stands at 3.3 percent year over year, which pressures consumer spending and could limit discretionary healthcare expenditures. This economic backdrop forces Pfizer to navigate tighter margins while maintaining its innovative pipeline, particularly in specialty medicines and rare diseases, where competition from generics is intensifying.
Financially, Pfizer's recent performance raises red flags for investors. The company reported a revenue decline to $62.58 billion in FY2025, down from $63.63 billion in FY2024. EBITDA also fell significantly, from $18.13 billion to $15.10 billion. These figures suggest that Pfizer is struggling to sustain profitability amid a challenging market. The payout ratio of 125.75 percent further complicates the picture, indicating that the company may be overextending itself in dividend payments, which could jeopardize future growth and financial stability.
Ultimately, the combination of declining cash flow per share and an extended cash conversion cycle signals potential liquidity issues. With a current ratio of 1.16, Pfizer has only a slight buffer against short-term liabilities. Investors should remain vigilant, as these financial strains could hinder the company's ability to invest in new therapies and maintain its competitive edge in the pharmaceutical sector.
Outlook
Pfizer's path forward hinges on its ability to navigate a challenging economic landscape marked by rising inflation and fierce competition. The company's recent focus on artificial intelligence in cancer care represents a strategic pivot that could enhance its product offerings and improve patient outcomes. This innovation may not only attract new customers but also solidify Pfizer's reputation as a leader in biotechnology. However, the mixed performance in earnings compared to competitors raises questions about whether these advancements will translate into sustained profitability.
As Pfizer reduces its physical office footprint and embraces remote work, it aims to streamline operations and cut costs. This move could improve efficiency, but it also reflects a broader trend in the pharmaceutical industry where companies must balance innovation with fiscal responsibility. Investors should closely monitor how these operational changes impact Pfizer's financial health, particularly in light of its recent cash generation challenges. The upcoming quarters will be critical as the company seeks to stabilize its revenue streams and respond to the pressures of a competitive market. Watch for updates on product launches and financial performance to gauge Pfizer's ability to adapt and thrive in this evolving environment.
Red & Green Flags
This section distills all of the report's positives (green flags), negatives (red flags) and open questions (unknowns) into one place. The Overall view reflects a read of the evidence across the full report; it is not a simple tally of the lists below.
Green Flags
- Pfizer has a strong market capitalization of $153.02 billion.
- The company maintains a price-to-earnings ratio of 19.68, indicating moderate valuation.
- Pfizer's return on equity has increased over the period, reflecting improved profitability.
- Earnings per share stand at $1.37, showcasing solid performance.
- The company has increased its revenue per share, operating cash flow per share, and free cash flow per share over the period.
- Pfizer's debt-to-equity ratio is manageable at 0.78, indicating a balanced capital structure.
- The cash and cash equivalents amount to $1.14 billion, providing liquidity.
- Pfizer's focus on artificial intelligence in cancer care may open new revenue streams.
- The decision to reduce physical office space aims to optimize operational efficiency and reduce costs.
Red Flags
- Revenue declined to $62.58 billion in FY2025 from $63.63 billion in FY2024.
- EBITDA fell significantly from $18.13 billion to $15.10 billion, indicating profitability challenges.
- The payout ratio of 125.75 percent raises concerns about sustainability of dividend payments.
- Operating cash flow per share has decreased, signaling cash generation challenges.
- The cash conversion cycle has lengthened, indicating inefficiencies in working capital management.
- Days of inventory outstanding have increased, suggesting potential inventory management issues.
- Days of payables outstanding have risen, indicating slower payments to suppliers.
Unknowns
- The impact of Pfizer's recent strategic pivot towards artificial intelligence on long-term profitability remains uncertain.
- It is unclear how the reduction in physical office space will affect employee productivity and company culture.
- The future performance of Pfizer's innovative pipeline in specialty medicines and rare diseases is not guaranteed.
9 green flags, 7 red flags, 3 unknowns.
Overall view: Bearish/Neutral.
Why this view:
- Pfizer reported a revenue decline to $62.58 billion in FY2025, indicating struggles to maintain profitability.
- The payout ratio of 125.75 percent raises concerns about the sustainability of dividend payments amid financial pressures.
- Declining cash flow per share and an extended cash conversion cycle suggest potential liquidity issues that could hinder operational efficiency.
Action Checklist
Below are the next research steps a retail investor should consider based on this report.
Disclaimer
This Company Report is based on publicly available information and original research, and is provided for informational purposes only. It does not constitute financial, investment, or legal advice, nor an offer or solicitation to buy or sell any security. Readers should conduct their own due diligence and consult qualified advisors before making any investment decisions. Company performance can change rapidly and past results are not a guarantee of future outcomes. The author and publisher accept no responsibility for any actions taken based on this report.